Month: August 2025

Decent Holding Inc. Announces First Half of Fiscal Year 2025 Financial Results

Written by Customer Service on August 13, 2025. Posted in Public Companies.

YANTAI, China, Aug. 13, 2025 (GLOBE NEWSWIRE) — Decent Holding Inc. (NASDAQ: DXST) (“Decent” or the “Company”), an established wastewater treatment services provider in China, today announced its unaudited financial results for the first half of fiscal year 2025 ended April 30, 2025. Financial Highlights for the First Half of Fiscal Year 2025Total revenue increased by 147.3% to approximately $5.5 million, from approximately $2.2 million in the prior-year period. Gross profit increased by 170.5% to approximately $1.5 million, from approximately $0.6 million; gross margin improved to 27.5% from 25.1% in the prior year. Net loss was approximately $0.5 million and $0.02 million for the six months ended April 30, 2025 and 2024, respectively.Mr. Dingxin Sun, Chairman of Decent Holding Inc. commented: “Our first-half performance underscores...

UCLA, Rutgers, and Manhattan School of Music are Among the Winners of the Kaltura Digital Engagement Awards in Education 2025

Written by Customer Service on August 13, 2025. Posted in Public Companies.

Announced at Kaltura Connect in Education 2025, which showcased forward-thinking uses of AI and video in education, the awards recognize educators and institutions advancing digital engagement, accessibility, and personalization through Kaltura’s AI Video Campus solutions New York, Aug. 13, 2025 (GLOBE NEWSWIRE) — Kaltura (Nasdaq: KLTR), the AI Video Experience Cloud, has announced the winners of the 2025 Kaltura Digital Engagement Awards in Education. The awards were presented at the annual Kaltura Connect in Education conferences that brought together hundreds of academic leaders to explore the evolving role of video, digital engagement, and AI in higher education. This year, Kaltura brought its education conference to world-recognized universities, including The University of Michigan in Ann Arbor, Michigan, Rutgers Business...

Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates

Written by Customer Service on August 13, 2025. Posted in Earnings Releases And Operating Results.

Continuing to enroll nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the retina; initial clinical data is expected in Q4 2025 Cash and cash equivalents of $88.4M as of June 30, 2025, expected to fund operations into Q4 2026 PALO ALTO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) — Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced financial results for the second quarter ended June 30, 2025, and provided a business update. “We continued to enroll treatment-naïve nAMD patients in our open-label Phase 1 clinical trial...

LiqTech International Announces Second Quarter 2025 Financial Results

Written by Customer Service on August 13, 2025. Posted in Earnings Releases And Operating Results.

BALLERUP, Denmark, Aug. 13, 2025 (GLOBE NEWSWIRE) — LiqTech International, Inc. (Nasdaq: LIQT) (“LiqTech”), a clean technology company that manufactures and markets highly specialized filtration technologies, today announced its financial results for the second quarter of 2025 for the period ended June 30, 2025. Recent Financial HighlightsQ2 2025 revenue of $5.0 million, an increase of 11% increase from $4.5 million in Q2 2024, and a sequential increase of 7% from $4.6 million in Q1 2025. Q2 2025 net loss of $(2.0) million compared to $(2.1) million in Q2 2024. Ending cash balance of $8.7 million on June 30, 2025.OutlookThe Company expects Q3 2025 revenue to be between $3.8 million and $4.2 million, which would equate to a 52% to 68% increase from Q3 2024. The Company expects full year 2025 revenue to be between...

Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Written by Customer Service on August 13, 2025. Posted in Earnings Releases And Operating Results.

Company Initiates Combination Trial and Strengthens Balance Sheet to Support Continued Clinical Progress NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) — Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announces financial results for the second quarter ended June 30, 2025, and provides a corporate update. Jeffrey Meckler, Indaptus Therapeutics’ Chief Executive Officer, commented, “This quarter marks a major clinical inflection point for Indaptus. In under four years since our founding, we have progressed from IND-enabling studies to an active combination trial in patients. This pace of development is a testament to the dedication of the small, but focused Indaptus Team. A few weeks ago, we dosed...

Base Carbon Reports Second-Quarter 2025 Operating and Financial Results

Written by Customer Service on August 13, 2025. Posted in Earnings Releases And Operating Results.

TORONTO, Aug. 13, 2025 (GLOBE NEWSWIRE) — Base Carbon Inc. (Cboe CA: BCBN) (OTCQX: BCBNF) with operations through its wholly-owned subsidiary, Base Carbon Capital Partners Corp. (“BCCPC”, together, with affiliates, “Base Carbon”, or the “Company”), is pleased to announce its second-quarter 2025 consolidated financial results and operational highlights. The Company will host an investor town hall in September, with details to follow over the coming weeks. All financial references are denominated in U.S. dollars, unless otherwise noted. Company Highlights:5th consecutive quarter of carbon credit sales revenue with net cash proceeds of $1.0 million from Vietnam cookstove carbon credit monetization.Subsequent to quarter end, the Company received into inventory 192,810 carbon credits from the Rwanda cookstoves project, increasing...

Nexxen Reports Second Quarter 2025 Financial Results

Written by Customer Service on August 13, 2025. Posted in Earnings Releases And Operating Results.

Generated record Q2 Contribution ex-TAC, programmatic revenue and CTV revenue Increased Adjusted EBITDA Margin to 34% of Contribution ex-TAC from 32% in Q2 2024 Renewed and expanded strategic partnership with VIDAA in Q3 2025 through at least the end of 2029, and increasing investment in VIDAA by $35 million to accelerate their North American CTV and data footprint NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) — Nexxen International Ltd. (NASDAQ: NEXN) (“Nexxen” or the “Company”), a global, flexible advertising technology platform with deep expertise in data and advanced TV, announced today its financial results for the three and six months ended June 30, 2025. Q2 2025 Financial HighlightsRecord Q2 Contribution ex-TAC of $87.8 million, up 6% year-over-year Record Q2 programmatic revenue of $85.0 million, up 8% year-over-year Record...

PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Written by Customer Service on August 13, 2025. Posted in Earnings Releases And Operating Results.

Positive Phase 3 SHIELD II Trial Results – D-PLEX₁₀₀ successfully met its primary efficacy endpoint and demonstrated 58% reduction in SSI NDA submission expected in Q1 2026 Unveiled a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Obesity and Diabetes Market Successful Warrant Exercise Significantly Strengthened Balance Sheet with Cash Runway into 2026 Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results for the three and six months ended June 30, 2025. Recent Corporate Highlights:Positive Phase 3 Data and Additional Clinical Insights: Reported...

BrainsWay Reports Second Quarter 2025 Financial Results and Operational Highlights

Written by Customer Service on August 13, 2025. Posted in Earnings Releases And Operating Results.

Achieved record quarterly revenue of $12.6 million in Q2 2025, an increase of 26% compared to Q2 2024 Operating profit totaled $0.6 million and Adjusted EBITDA rose to $1.5 million, Raised full-year 2025 Revenue and EBITDA guidance Remaining performance obligations increased by 25% YOY to $62 millionConference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, Aug. 13, 2025 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported second quarter 2025 financial results and provided an operational update. Recent Financial and Operational HighlightsRevenue in the second quarter of 2025 increased 26% to $12.6 million, compared to the second quarter of 2024. Of recent...

Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Written by Customer Service on August 13, 2025. Posted in Earnings Releases And Operating Results.

Denifanstat met all primary and secondary endpoints in Phase 3 clinical trial in moderate to severe acne conducted by license partner Ascletis in China Initiated first-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 being developed for acne in the U.S. Phase 1 clinical trial to evaluate the pharmacokinetics (PK) of a combination of denifanstat and resmetirom expected to initiate in 2H 2025; data readout expected 1H 2026 SAN MATEO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today reported financial results for the quarter ended June 30, 2025, and provided recent corporate updates. “We are making strong progress advancing our differentiated therapeutics,...

Month: August 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals